AstraZeneca is planning to improve the use of artificial intelligence, robots and digital applications so that the efficiency of disease treatment in China can be supported in terms of changes applied to it, along with improvements to be implemented to the functioning of healthcare services.
Potentially, such products are supposed to improve cancer diagnostics, allow diabetics for accessing products of a high quality and harness artificial intelligence to the improvement process of transporting patients with a suspected heart attack.While the undertaking itself is not expected to directly raise the company's drug sales on the Chinese market , it secures more awareness of AstraZeneca among patients on the same market.
"We will get benefit, as we will have better relationships with doctors and hospital managers and also because we will diagnose more patients, making it possible to treat them more effectively" said Soriot at the World Internet of Things Exposition in Wuxi, China.
It does not mean that AstraZeneca is not doing well in the Far East.Actually, the company has doubled its sales since 2012, while 18% of its current revenue comes precisely from China.At the beginning of the previous year, the company also launched Tagrisso - a therapy for lung cancer ? on the Chinese market. According to some analysts, it may raise the global sales of the drug to a level exceeding USD 5 billion throughout the next five years.
At the beginning of this year, AstraZeneca managed to sign two deals with Chinese Internet giants - Alibaba and Tencent.A partnership with Alibaba will help develop "smart" healthcare services, meant as composed of education of patients, prevention of diseases or artificial intelligence-assisted examination and diagnosis.Consecutively, the cooperation with Tencent will be centered around the use of big data for the purpose of combating the sales of counterfeit drugs on the Internet.